Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Why the study?
Does adjuvant mitotane prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma?
Population
177 patients with adrenocortical cancer who had undergone radical surgery at 8 centers in Italy and 47…
Comparison
Adjuvant mitotane administered after radical… vs No adjuvant treatment after surgery
Design
Cohort
Authors
Discussion
Loading...
Member takes
Overview
Supports adjuvant mitotane after resected adrenocortical carcinoma; leaves open confirmation in randomized trials.
Structured PICO
Does adjuvant mitotane prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma?
P
Population
177 patients with adrenocortical cancer who had undergone radical surgery at 8 centers in Italy and 47 centers in Germany between 1985 and 2005.
I
Intervention
Adjuvant mitotane administered after radical surgery
C
Comparator
No adjuvant treatment after surgery (control group 1: 55 Italian patients; control group 2: 75 German patients)
O
Outcome
Recurrence-free survivalhard clinical
Adjuvant mitotane significantly prolongs recurrence-free survival in patients with radically resected adrenocortical carcinoma compared to no adjuvant treatment.
Cite This Study
Terzolo et al. (2007) studied this question.